RTOG 0232: A phase III study comparing combined external beam radiation and transperineal interstitial prmanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic cancer

The primary goal of this study is to evaluate the benefit in overall survival of external beam radiation plus interstitial brachytherapy versus interstitial brachytherapy alone among selected patients with intermediate risk prostatic carcinoma.

You may be eligible to participate in this study if you:

• Have histologically confirmed adenocarcinoma of the prostate, clinical stage T1c-T2b (AJCC 6th Edition, see Appendix III), N0, M0. Lymph node evaluation by either CT, MRI, or node dissection is required
• Have a Zubrod performance status 0-1
• Be a patient with intermediate risk prostate cancer determined by one of the following combinations: Gleason < 7, PSA must be 10-20; Gleason 7, PSA must be < 10

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.